



BioPlex® 2200 ANA Screen with MDSS

Fully-automated simultaneous autoantibody screen and identification

Systemic autoimmune diseases present a complex path to diagnosis with the outcome ranging from relatively benign disorders to life-threatening organ dysfunction. Diagnosis requires a combined assessment of both clinical symptoms and abnormalities of autoantibody tests. By detecting only clinically significant autoantibodies, the BioPlex®2200 ANA Screen will help the clinician to better diagnose systemic autoimmune diseases such as:

- Systemic Lupus Erythematosus (SLE)
- Mixed Connective Tissue Disease (MCTD)
- Sjögren's Syndrome (SS)
- Scleroderma (Systemic Sclerosis)
- Dermatomyositis (DM)
- Polymyositis (PM)
- CREST syndrome

Consolidated into 1 Kit:

ANA Screen*

Antibodies to:

- dsDNA (quant)
- Chromatin
- Ribosomal Protein
- SS-A (52 and 60)**
- SS-B
- Sm
- Sm/RNP
- RNP (A and 68)**
- Scl-70
- Jo-1
- Centromere B

* ANA Screen is a composite roll up of all individual results



** Individual results available outside US only



BioPlex® 2200 ANA Screen



Medical Decision Support Software (MDSS)



Up to **12** (14 outside US) test results/sample
Up to **1,200** (1,400 outside US) results/hour

MDSS – An optional laboratory tool

MDSS uses an interpretative algorithm based on over 15,000 test results from a diverse cohort of over 1,400 clinically characterized patients.

Benefits of Multiplex ANA Testing

- High throughput multiplex testing improves workflow efficiencies and eliminates hands-on steps
- Provides flexibility to screen and confirm specific autoantibodies with one kit
- Time to first result in approximately 45 minutes – reduces turnaround time
- Ready-to-use multiplexed calibrators and controls with curve stability up to 30 days reduces overall costs

Quality and Performance

- Excellent dsDNA quantitation when compared to the WHO W/o 80 standard resulting in a correlation coefficient > 99.9%
- Good overall agreement with commercially available EIA methods for individual autoantibodies (86%-100%)
- Excellent lot-to-lot reproducibility with within-run %CV < 5% and between-run %CV < 9%
- Three internal quality beads processed with every sample to ensure system and results reliability
- MDSS provides enhanced analysis of patient antibody results using predefined profiles that have been correlated with SLE, MCTD, Sjogren's Syndrome, Systemic Sclerosis and Polymyositis

Ordering Information

Catalog No.	Description	
665-1150	BioPlex®2200 ANA Screen Reagent Pack.....	1 pack
663-1101	BioPlex®2200 ANA Screen Calibrator Set	1 set
663-1131	BioPlex®2200 ANA Screen Control Set	1 set



Bio-Rad Laboratories

For further information, please contact the Bio-Rad office nearest you or visit our website at www.bio-rad.com/diagnostics

Clinical Diagnostics Group

Website www.bio-rad.com/diagnostics U.S. 1-800-224-6723 Australia 61-2-9914-2800 Austria 43-1-877-8901 Belgium 32-9-385-5511 Brazil 5521-3237-9400 Canada 1-514-334-4372 China 86-21-61698500 Czech Republic 420-241-430-532 Denmark +45-4452-1000 Finland 358-9-804-22-00 France 33-1-47-95-60-00 Germany +49-(0)89-318-840 Greece 30-210-7774396 Hong Kong 852-2789-3300 Hungary +36-1-459-6100 India 1800-180-1224 Israel 972-3-9636050 Italy +39-02-216091 Japan 81-3-6361-7070 Korea 82-2-3473-4460 Mexico +52 (55) 5488-7670 The Netherlands +31-318-540666 New Zealand 64-9-415-2280 Norway 47-23-38-41-30 Poland 48-22-3319999 Portugal 351-21-472-7700 Russia 7-495-721-14-04 Singapore 65-6415-3170 South Africa 27-11-442-85-08 Spain 34-91-590-5200 Sweden 46-8-555-127-00 Switzerland 41-61-717-95-55 Taiwan 886-2-2578-7189 Thailand 662-651-8311 United Kingdom +44-(0)20-8328-2000